Figure 2.

Protection efficacy of DMA2017 against CA16 challenge in suckling mice. (A) Groups of mice (n = 5) were infected with 54 CCID₅₀ BJCA08/CA16. One day post-challenge, the mice were treated with different doses of DMA2017 (10, 2, 0.4, 0.08 and 0.016 μg/g) via intraperitoneal route. The asterisk indicates significant differences at **P < 0.01 and ***P < 0.001. (B) Clinical symptoms of mice were monitored and recorded for 21 days.